ORLANDO, Fla., Sept. 21, 2016 /PRNewswire-USNewswire/ — Immune Therapeutics, Inc., a clinical-stage pharmaceutical company focused on the commercialization and development of the first affordable non-toxic immunodulator for the treatment of inflammatory diseases, immune-related disorders, and cancer, today announces the appointment of two new members to its Medical and Clinical Advisory Board comprised of: Joseph M. Chalil, MD and Mak Jawadekar, Ph.D., join Clifford A. Selsky, Ph.D., MD and Nicholas P. Plotnikoff Ph.D.
“The experts on our Advisory Board will work closely with the management team to advance the Company’s portfolio of novel immunotherapies. They join us at a critical time, as we are hoping to enter into a Phase 2b/3 clinical trial of IRT-013 for Crohn’s Disease in the U.S. and HIV and Cancer in Africa,” said Noreen Griffin President and Chief Executive Officer of Immune Therapeutics. “This team of accomplished Medical Scientific and clinical leaders complements the expertise of the management team and will collaborate with us on our goal of bringing these new and critical therapies to patients while addressing the issue of affordable non-toxic therapies – a growing global healthcare crisis.”
Initial Appointments to Immune Therapeutics, Inc. Medical Scientific and Clinical Advisory Board
Dr. Chalil MD, MBA, FACHE is Associate Director, Health Science Executives of Boehringer Ingelheim, the world’s largest privately held pharmaceutical company. Headquartered in Ingelheim, Germany, the Company operates globally in more than 50 countries. In 2012, Boehringer Ingelheim achieved net sales of 19.1 billion (USD); R&D expenditure in the business area of prescription medicines reached a quarter of its net sales.
In addition to his responsibilities at Boehringer Ingelheim, Dr. Chalil is the Co-Chair for the Industry Physician Committee of the American Association of Physicians of Indian Origin (AAPI) and has served as Scientific Advisor to AAPI for the past three years. AAPI is the second largest physician organization in the U.S. second only to AMA, and the largest ethnic medical organization in the country. Dr. Chalil is also a Consultant in HIV/STDs President, AIDS Society of India (ASI).
As the former CEO of Clinical Consultants International, he represented prominent healthcare companies, including GE Healthcare, Genpact, HIRCO Group, Godrej Ltd., KLE University, Somaiya Group, Pushpanjali Crosslay Hospital, Excel Life Sciences and various international pharmaceutical firms over the past decade.
Dr. Chalil completed his higher studies in University of Medicine and Dentistry of New Jersey, Davenport University, JJM Medical College and Baylor College of Medicine. He has been a Visiting Professor at various Universities and serves on various company Boards.
Mak Jawadekar, Ph.D., is an independent pharmaceutical industry consultant and currently serves on several U.S. and international company boards in scientific advisory and business management capacities. After completing his Ph.D. (Pharmaceutics) at the University of Minnesota, he started working at Pfizer, Inc., and his tenure was over 28 years in length until March 2010, when he opted to take an early retirement. Mak was a Director, R & D Portfolio Management & Performance with the World Wide R & D Division of Pfizer Inc. in Groton/New London, CT, where he was leading efforts in R&D benchmarking metrics for speed, quality and costs to enhance Pharmaceutical R&D productivity.
Mak also advised Pfizer’s R&D business on system solution approaches and best practices, and served as an advisor to Pfizer’s President of Global R&D on Asia-related strategic matters. Prior to that, he spent many years with Pfizer’s Pharmaceutical Sciences Group as a leader, where he held responsibility for Strategic Outsourcing of Drug Products activities and Drug Delivery Technology Assessment functions. Mak also managed strategic-level decisions on external alliances and collaborations, including partnerships, due diligence activities, and licensing and development. His extensive previous Bench R & D experience includes dosage form development/formulations/drug delivery R&D, clinical manufacturing, tech transfer and scale-up operations, and worked closely with Pfizer Global Manufacturing and Consumer Health care divisions.
About Immune Therapeutics, Inc.:
Immune Therapeutics, Inc., is a biotechnology company dedicated to combat chronic, life-threatening diseases by activating and modulating the body’s immune system using our patented immunotherapy. Our products and immunotherapy technologies are designed to harness the power of the immune system to enhance treatment of cancer, infections such as HIV/AIDS, chronic inflammatory diseases, and autoimmune diseases.
IMUN’s proprietary technology and therapies include treatment of a wide range of cancers. Our most advanced clinical programs involve immunotherapy with met-enkephalin (MENK) (sometimes referred to as opioid growth factor) and our Low Dose Naltrexone product (LDN) or LodonalTM, which have been shown to stimulate immune systems even in patients with advanced cancer.
We are pursuing additional investigations for MENK and LDN as viable treatments for autoimmune conditions such as rheumatoid arthritis and multiple sclerosis; as an adjunct in cancer patients undergoing chemotherapy, radiation treatments or surgery; and as a complement to antibiotics in the treatment of a variety of infectious diseases, including patients with HIV/AIDS, in combination with retroviral drug therapy.
Forward Looking Statements
This release contain forward-looking statements. Actual results may differ from those projected due to a number of risks and uncertainties, including, but not limited to the possibility that some or all of the matters and transactions considered by Immune Therapeutics may not proceed as contemplated, and by all other matters specified in Immune Therapeutic’s filings with the Securities and Exchange Commission. These statements are made based upon current expectations that are subject to risk and uncertainty. Immune Therapeutics does not undertake to update forward-looking statements in this news release to reflect actual results, changes in assumptions or changes in other factors affecting such forward-looking information. Assumptions and other information that could cause results to differ from those set forth in the forward-looking information can be found in the Immune Therapeutic’s filings with the Securities and Exchange Commission, including its recent periodic reports.